

REVIEW

Vestibular migraine: diagnosis challenges and need for targeted treatment

Migrânea vestibular: desafios diagnósticos e a necessidade de tratamentos específicos

Felipe Barbosa, Thaís Rodrigues Villa

ABSTRACT

Approximately 1% of the general population suffers from vestibular migraine. Despite the recently published diagnostic criteria, it is still underdiagnosed condition. The exact neural mechanisms of vestibular migraine are still unclear, but the variability of symptoms and clinical findings both during and between attacks suggests an important interaction between trigeminal and vestibular systems. Vestibular migraine often begins several years after typical migraine and has a variable clinical presentation. In vestibular migraine patients, the neurological and neurotological examination is mostly normal and the diagnosis will be based in the patient clinical history. Treatment trials that specialize on vestibular migraine are scarce and therapeutic recommendations are based on migraine guidelines. Controlled studies on the efficacy of pharmacologic interventions in the treatment of vestibular migraine should be performed.

Keywords: migraine; vestibular migraine; dizziness; vertigo.

RESUMO

Cerca de 1% da população apresentam o diagnóstico de migrânea vestibular. Apesar dos critérios diagnósticos terem sido publicados recentemente, ainda é uma condição subdiagnosticada. Os mecanismos neurais exatos da migrânea vestibular ainda não estão claros, mas a variabilidade dos sintomas e achados clínicos durante e entre os ataques sugere uma interação importante entre os sistemas trigeminal e vestibular. A migrânea vestibular geralmente começa alguns anos após a migrânea típica e tem apresentação clínica variável. Em pacientes com migrânea vestibular, o exame neurológico e otoneurológico são geralmente normais e o diagnóstico é baseado na história clínica do paciente. Estudos sobre tratamento da migrânea vestibular são escassos e recomendações terapêuticas são baseadas em diretrizes do tratamento da migrânea. Estudos controlados sobre a eficácia das intervenções farmacológicas para o tratamento da migrânea vestibular devem ser realizados.

Palavras-chave: migrânea; migrânea vestibular; tontura; vertigem.

Dizziness is one of the most common complaints in clinical practice, affecting 20-30% of the general population¹ and is often reported by patients with migraine². The prevalence of migraine is higher in patients with dizziness², and benign recurrent vertigo is the most prevalent type of dizziness in this population^{3,4}. The relationship between dizziness and migraine was first described by the ancient Greek physician Aretaeus of Cappadocia in 131 BC⁵. In 1873, Edward Liveing observed an association between migraine and dizziness in some of his patients⁶. However, detailed observation of this association was initiated only in the last 30 years. Since the first studies of Kayan et al. about the vestibular manifestations of migraine⁷ the number of articles addressing the relationship between vertigo and migraine has grown exponentially in the last 25 years^{8,9}. Different terms have been used to designate the relationship of vertigo and migraine including migraine-associated

vertigo, migraine-associated dizziness, migraine-related vestibulopathy, migrainous vertigo, benign recurrent vertigo. More recently the term vestibular migraine (VM) was defended as a condition that covers the vestibular manifestations that may occur in migraine, avoiding confusion with nonvestibular dizziness that may also be associated with migraine¹⁰.

EPIDEMIOLOGY

Despite vestibular migraine is one of the most common diagnoses in dizziness units (the second most common cause of recurrent vertigo after benign paroxysmal positional vertigo (BPPV)) accounting for 6-9% of all diagnoses, it is still underdiagnosed^{2,9}. In a study conducted by a specialized clinic in Switzerland, dizziness was diagnosed as vestibular

Universidade Federal de São Paulo, Departamento de Neurologia e Neurocirurgia, Ambulatório de Migrânea Vestibular, São Paulo SP, Brasil.

Correspondence: Thaís Rodrigues Villa; Rua Pedro de Toledo, 650; 04039-002 São Paulo SP, Brasil; E-mail: contato@cefaleiaweb.com.br

Conflict of interest: There is no conflict of interest to declare.

Received 29 January 2015; Received in final form: 30 November 2015; Accepted 13 January 2016.

migraine in 20.2% of patients, although VM was previously suspected by the requesting physicians in only 1.8%. The diagnosis of “uncertain dizziness” accounted for almost 60% of patients¹¹. In another study in Germany, with 33 patients, two-thirds of patients diagnosed with VM had consulted a doctor because of vertigo, but only 20% were diagnosed with VM. The remaining patients were diagnosed with other diseases such as anemia, diabetes, hypovolemia¹². Vestibular migraine has a year prevalence of 0.89% and represents about 10% of patients treated for either migraine and dizziness¹³. Hsu and colleagues reported a year prevalence of vestibular migraine in women aged 40-54 years of 5%¹⁴. Forty percent of patients with vestibular migraine reported missing work because of their symptoms, showing the impact of the disease on daily life¹². Vestibular migraine can occur at any age, but the average age of onset of dizziness in migraine is about 40, and a first attack late age in 72 years has been reported. It has a female predominance, the female and male ratio of 5: 1^{2,12,15}. In older patients, particularly post-menopausal women, typical migraine attacks are sometimes replaced by isolated episodes of vertigo, dizziness or transient feeling of imbalance¹⁶. In a population-based study, the prevalence of recurrent vertigo probably related to migraine was estimated at 2.8% in children with 6-12 years¹⁷. Vestibular migraine is diagnosed more often in children than adults (35% vs 6%)⁸. The most common cause of vertigo in children is benign paroxysmal vertigo, which has a strong association with a family history of migraine and may predict the development of typical migraine¹⁸.

Pathophysiology

The exact neural mechanisms of vestibular migraine are still unclear. The variability of symptoms and clinical findings both during and between attacks suggests that migraine interacts with the vestibular system at various levels¹⁹.

The vestibular nuclei receive noradrenergic inputs from the locus ceruleus and serotonergic inputs from the dorsal raphe nucleus^{20,21}. Therefore, activation of these nuclei during migraine attacks may give rise to vestibular symptoms. Since the caudalis trigeminal nucleus also has reciprocal connections with the vestibular nuclei, and neurogenic inflammation of the trigeminal system is believed to be a mechanism of migraine, trigeminal activation may provoke vestibular symptoms during migraine attacks. Trigeminal activation by painful electrical stimulation of the forehead produced spontaneous nystagmus in migraine patients, but not in controls, indicating that those with migraine have a lowered threshold for crosstalk between these neighboring brainstem structures²². Shin and colleagues studied 2 patients with vestibular migraine who underwent FDG-PET images. During attacks of vestibular migraine, the increased metabolism of the temporo-parieto-insular areas and bilateral thalamic indicated activation of the vestibulothalamo-vestibulocortical

pathway, and the decreased metabolism in the occipital cortex may represent reciprocal inhibition between the visual and vestibular systems²³. Another image study comparing vestibular migraine patients with migraine without aura (MwoA) and healthy controls (HC) showed that patients with VM showed a significantly increased left medio-dorsal thalamic activation in response to an ipsilateral vestibular stimulation, relative to both HC and patients with MwoA. Furthermore, the magnitude of left thalamic activation was uniquely correlated with frequency of migraine attacks in patients with VM²⁴. The role of mediadorsal thalamus in VM pathophysiology could reflect the involvement of a dysfunctional vestibulo-thalamocortical network, which overlaps with the migraine circuit¹⁹.

Cortical spreading depression (CSD) in both multisensory vestibular areas of the cortex and brainstem was used as an explanation for ‘aura’-like dizziness/vertigo attacks with consecutive headache. However, an isolated CSD, which is limited to the brain stem without causing any other symptoms, is not very likely²⁵.

Some authors suggested a genetic inheritance. A linkage analysis in a four-generation family with 10 affected individuals mapped the locus for vestibular migraine to chromosome 5q35²⁶. In a larger study, familial vestibular migraine was found to be genetically heterogeneous with a subgroup linking to chromosome 22q12²⁷.

The most current pathophysiologic model of vestibular migraine is summarized in Figure.

Diagnostic criteria

The International Headache Society (IHS) and the Bárány-Society (International Society for Neuro-Otology) created a consensus document with diagnostic criteria for vestibular migraine, which was added in the appendix of the new ICHD-3 beta version of the International Headache Classification²⁸ (Table 1).

Clinical presentation

Vestibular migraine often begins several years after typical migraine^{2,15}. In a previous study, migraine manifested before VM in 74% of participants and in more than half of these (52%) migraine was preceded by VM by more than 5 years, and in 26% even by more than 10 years. The vast majority of patients (85%) had experienced both VM and migraine during the last 12 months¹². Vestibular migraine is more common in patients without aura than in patients with aura²⁹. The most frequent vestibular symptoms associated with migraine are spontaneous vertigo in 67% followed by positional vertigo in 24% of these patients¹². Other commonly described symptoms are: imbalance, head motion intolerance, visual vertigo and non-vertiginous dizziness such as lightheadness or “boat like” rocking^{13,30}.

The duration of attacks can vary from a few seconds (10% of patients) to some minutes (30% of patients), some




Figure. Summary of pathophysiologic model of vestibular migraine.

hours (30% of patients) and even up to a few days (30% of patients)²⁵. Only 10-30% of patients described a typical vestibular aura. Vestibular symptoms can occur before, during or after the migraine attack and in 30% of the patients the two symptoms never occurred together^{2,31}. Some patients reported vertigo as the most disabling symptom and only report a slight felling of pressure in the head replacing a typical migraine headache^{32,33}.

Auditory symptoms, including hearing loss, tinnitus, and aural pressure have been reported in up to 38% patients with vestibular migraine. Hearing loss is usually mild and transient, without or with only minor progression in the course of the disease^{2,34,35}.

Radtke et al. reassessed 61 patients with definitive VM according to validated diagnostic criteria after a follow-up time of 9 years and their findings are shown on Table 2³⁶.

Episodes of vestibular migraine can be brought about by the same triggers as those for migraine headache, including menstruation, irregular sleep, stress, physical exertion,

dehydration, food and drinks, and intense sensory stimulation, mostly movement²⁹.

In most patients, the neurologic and otologic examination is normal during the interictal phase³². About 10 to 30% of patients with vestibular migraine have unilateral hypoexcitability to caloric stimulation and 10% have directional preponderance of nystagmus responses. Such findings, however, are not specific for vestibular migraine, because they can be found also in migraine patients without vestibular symptoms and in many other vestibular syndromes³⁷. In one study, patients with vestibular migraine became nauseous after caloric testing four times more often than migraine patients and patients with other vestibular disorders³⁸. A neuro-otologic study of 20 patients during the acute phase of vestibular migraine showed pathological nystagmus in 14 patients, mostly central spontaneous or positional nystagmus. Three patients had a peripheral spontaneous nystagmus and a unilateral deficit of the horizontal

Table 1. Vestibular migraine: diagnostic criteria.

A. At least five episodes fulfilling criteria C and D.
B. A current or past history of 1.1 Migraine without aura or 1.2 Migraine with aura.
C. Vestibular symptoms of moderate or severe intensity, lasting between 5 minutes and 72 hours.
D. At least 50% of episodes are associated with at least one of the following three migrainous features:
1. headache with at least two of the following four characteristics:
a) unilateral location;
b) pulsating quality;
c) moderate or severe intensity;
d) aggravation by routine physical activity.
2. photophobia and phonophobia;
3. visual aura.
E. Not better accounted for by another ICHD-3 diagnosis or by another vestibular disorder.

ICHD-3: International Classification of Headach Disorders 3rd edition (beta version).

Table 2. Clinical characteristics of vertigo and concomitant symptoms in 61 patients with definite vestibular migraine.³⁶

	Initial presentation (%)	Follow up (%)
Type of vertigo		
Spontaneous	85	95
Spinning	75	82
Positional	39	80
Head-Motion-Induced	61	84
Unsteadiness	66	90
Duration of vertigo attacks		
< 1 min	31	75
1-5 min	30	56
5-60 min	34	64
< 24h	49	74
> 24h	52	69
Cochlear symptoms during vertigo spells		
Tinnitus	10	33
Aural fullness	13	26
Hearing loss	12	26
Migraine symptoms during vertigo attacks		
Headache	75	90
Photophobia	59	80
Phonophobia	54	77
Aura	18	44

vestibulo-ocular reflex. Imbalance was observed in all patients except one³⁹. Since there are no specific abnormalities in vestibular migraine, in general practice the diagnosis will be based in the patient clinical history.

Differential diagnosis

The main differential diagnosis of VM is Ménière's disease (MD). An association between MD and migraine was already suggested by Prosper Ménière himself in 1861⁴⁰. Some studies have ratified a higher prevalence of migraine in patients with MD^{41,42}, almost 30% of patients with Ménière syndrome may also have VM⁴¹. The overlap or coexistence of both diseases may make the patient's diagnosis difficult and the most reliable distinguishing feature is the low-frequency hearing loss in MD⁴². In general, MD distinguished from vestibular migraine by symptoms of ear fullness or pain preceding the attack or at attack onset, and accompanying tinnitus and/or hearing loss during the episode. These symptoms are not very prominent in vestibular migraine^{41,42}.

Endolymphatic hydrops is the primary pathological entity seen in Ménière's disease⁴³. Recent progress has made it possible to reliably visualize endolymphatic hydrops in living humans by employing a Locally Enhanced Inner ear MRI technique. Gurkov et al. investigated the occurrence of endolymphatic hydrops (EH) in patients with VM and auditory symptoms. Nineteen patients with definite or probable VM and auditory symptoms were examined by locally enhanced inner ear MR imaging. Of the 19 included patients, four patients (21 %) demonstrated evidence of cochlear and vestibular endolymphatic hydrops⁴⁴.

In contrast, Nakada et al. investigated endolymphatic hydrops in seven patients with definitive VM and 7 patients with MD. EH was not found in VM patients but all patients with MD showed significant EH⁴⁵.

BPPV is the most common cause of recurrent vertigo⁴⁶. Episodic vertigo related to migraine occurs several times per year or month with a duration of some hours up to few days, whereas BPPV leads to episodes of short lasting vertigo typically lasting weeks to months without therapy⁴⁷. During acute attacks of vertigo, the analysis of the positional nystagmus usually permits differentiation of positional VM from BPPV⁴⁷.

Transient ischemia within the vertebrobasilar system is a common cause of episodic vertigo in older people. It is abrupt in onset, usually lasts several minutes, and is frequently associated with nausea

and vomiting⁴⁸. Baloh studied 42 patients with vertigo in a neurotology service with the diagnosis of vertebrobasilar insufficiency and found that 62% had at least one episode of isolated vertigo and in 19% the transient ischemic attack began with an isolated episode of vertigo⁴⁹. Therefore, it is reasonable to investigate older patients with sudden onset of unilateral deafness and vertigo, particularly if there is a prior history of TIA, stroke, or known atherosclerotic vascular disease.

Basilar migraine requires at least two aura symptoms, which are assignable to the vertebrobasilar territory, lasting between 5 and 60 minutes and followed by a typical migraine headache²⁵. Less than 10% of the patients with VM meet the criteria for basilar type migraine².

Treatment

Current VM treatment recommendations are most based on expert opinions rather than on solid data from randomized controlled trials. Most therapeutic approaches are based on case reports, retrospective cohort studies and open labels trials. In general, the scientific literature suggests that drugs efficacious for prophylaxis of migraine are also appropriate for prophylaxis of vestibular migraine⁴⁹.

Neuhauser and colleagues suggested a benefit of zolmitriptan 2.5 mg in 38% of patients with vestibular migraine whereas in the placebo group a positive effect was seen in 22%. Unfortunately, the study had some limitations such as the large interval of confidence and the small number of patients recruited with only 17 reported attacks⁵⁰.

In another study, 48 patients with VM diagnose received flunarizine 10 mg daily along with betahistine and paracetamol during the migraine episodes and compared to the control group who received only the symptomatic treatment during the episodes. The frequency of vertiginous episodes showed a significant difference between the two groups, although the headache frequency and intensity did not improve in a significant degree⁵¹.

One retrospective single center open label investigation compared the effect of cinnarizine on VM and migraine with brainstem aura patients. Cinnarizine reduced the headache variables (frequency, duration and intensity) in both types of migraine with greater outcomes in the vestibular migraine group. Vertigo was also decreased in both groups with significant reduction in the VM group in the first month⁵².

One retrospective, open-label study investigated the efficacy of 100 mg lamotrigine in 19 patients (6 male, 13 female) with vestibular migraine over 3–4 months. The average vertigo frequency per month was reduced from 18.1 to 5.4, headache frequency dropped from 8.7 to 4.4, but did not reach statistical significance. Therefore, lamotrigine appears to mainly act on vestibular symptoms and only to a lesser extent on headaches⁵³.

A large retrospective cohort compared 100 VM patients with and without prophylactic migraine treatment. All

patients on prophylactic treatment showed a decrease of duration, intensity, and frequency of episodic vertigo as well as its associated features ($p < 0.01$). Medications used were beta-blocker, 49 patients, metoprolol (median dose 150 mg) or propranolol (median dose 160 mg), valproic acid, 6 patients (median dose 600 mg), topiramate, 6 patients (median dose 50 mg), butterbur extract, 4 patients (median dose 50 mg), lamotrigine, 3 patients (median dose 75 mg), amitriptyline 2 patients (75 to 100 mg), flunarizine, 1 patient (5 mg), and magnesium 3 patients (median dose 400 mg). The group without prophylactic therapy showed a reduction of vertigo intensity only⁵⁴. An ongoing trial will test the efficacy of metoprolol in vestibular migraine (Prophylactic treatment of vestibular migraine with metoprolol - PROVEMIG trial)⁵⁵.

Behavioral modifications can be tried. One retrospective study showed that 14% of 38 patients enrolled reported an improvement in symptoms after caffeine cessation⁵⁶.

Vestibular rehabilitation exercises were described to be beneficial in patients with vestibular migraine in addition to medical treatment or as stand-alone treatment option⁵⁷. Improvement in physical performance measures and self-perceived abilities after a 4-month vestibular physical therapy was observed in 14 patients with the diagnosis of migraine related vertigo⁵⁸. In another cohort study, patients with vestibular disorders with or without a history of migraine demonstrated improvements after nine weeks in both subjective and objective measures of balance after 15 minutes daily physical therapy⁵⁹.

Clinical implications

Vestibular migraine is quite prevalent but still underdiagnosed, and the impact on daily life activities and well-being is considerable. Treatment is not well established and therapeutic recommendations are based on migraine guidelines. The need of specific treatment is urgent. The migraine patient should be asked about vestibular symptoms by routine and controlled studies on the efficacy of pharmacologic interventions in the treatment of vestibular migraine should be performed.

References

1. Yardley L, Owen N, Nazareth I, Luxon L. Prevalence and presentation of dizziness in a general practice community sample of working age people. *Br J Gen Pract.* 1998;48(429):1131-5.
2. Neuhauser H, Leopold M, Brevern M, Arnold G, Lempert T. The interrelations of migraine, vertigo, and migrainous vertigo. *Neurology.* 2001;56(4):436-41. doi:10.1212/WNL.56.4.436
3. Lee H, Sohn SI, Jung DK, Cho YW, Lim JG, Yi SD et al. Migraine and isolated recurrent vertigo of unknown cause. *Neurol Res.* 2002;24(7):663-5. doi:10.1179/016164102101200726
4. Cha YH, Lee H, Santell LS, Baloh RW. Association of benign recurrent vertigo and migraine in 208 patients. *Cephalalgia.* 2009;29(5):550-5. doi:10.1111/j.1468-2982.2008.01770.x
5. Cal R, Bahmad F Jr. Migraine associated with auditory-vestibular dysfunction. *Braz J Otorhinolaryngol.* 2008;74(4):606-12. doi: 10.1016/S1808-8694(15)30611-X
6. Living E. On megrim, sick-headache, and some allied disorders. London, UK: Churchill, 1873.
7. Kayan A, Hood JD. Neuro-otological manifestations of migraine. *Brain.* 1984;107(4):1123-42. doi:10.1093/brain/107.4.1123
8. Furman JM, Marcus DA, Balaban CD. Migrainous vertigo: development of a pathogenetic model and structured diagnostic interview. *Curr Opin Neurol.* 2003;16(1):5-13. doi:10.1097/00019052-200302000-00002
9. Neuhauser, H.K., Lempert, T. Vertigo: epidemiologic aspects. *Semin Neurol.* 2009;9(5):473-81. doi:10.1055/s-0029-1241043

10. Brandt T, Strupp M. Migraine and vertigo: classification, clinical features, and special treatment considerations. *Headache Currents*. 2006;3(1):12-9. doi:10.1111/j.1743-5013.2006.00027.x
11. Geser R, Straumann D. Referral and final diagnoses of patients assessed in an academic vertigo center. *Front Neurol*. 2012;3:169. doi:10.3389/fneur.2012.00169
12. Neuhauser HK, Radtke A, Brevern M, Feldmann M, Lezius F, Ziese T et al. Migrainous vertigo: prevalence and impact on quality of life. *Neurology*. 2006;67:1028. doi:10.1212/01.wnl.0000237539.09942.06
13. Neuhauser H, Lempert T. Vertigo and dizziness related to migraine: a diagnostic challenge. *Cephalalgia*. 2004;24(2):83-91. doi:10.1111/j.1468-2982.2004.00662.x
14. Hsu LC, Wang SJ, Fuh JL. Prevalence and impact of migrainous vertigo in mid-life women: a community-based study. *Cephalalgia*. 2011;31(1):77-83. doi:10.1177/0333102410373152
15. Dieterich M, Brandt T. Episodic vertigo related to migraine (90 cases): vestibular migraine? *J Neurol*. 1999;246(10):883-92. doi:10.1007/s004150050478
16. Murdin L, Davies RA, Bronstein AM. Vertigo as a migraine trigger. *Neurology*. 2009;73(8):638-42. doi:10.1212/WNL.0b013e3181b38a04
17. Abu-Arafah I, Russell G. Paroxysmal vertigo as a migraine equivalent in children: a population-based study. *Cephalalgia*. 1995;15(1):22-5. doi:10.1046/j.1468-2982.1995.1501022.x
18. Sargent, EW. The challenge of vestibular migraine. *Curr Opin Otolaryngol Head Neck Surg*. 2013;21(5):473-9. doi:10.1097/MOO.0b013e3283648682
19. Balaban CD. Migraine, vertigo and migrainous vertigo: links between vestibular and pain mechanisms. *J Vestib Res*. 2011;21(6):315-21. doi:10.3233/VES-2011-0428
20. Schuerger RJ, Balaban CD. Organization of the coeruleo-vestibular pathway in rats, rabbits, and monkeys. *Brain Res Brain Res Rev*. 1999;30(2):189-217. doi:10.1016/S0165-0173(99)00015-6
21. Halberstadt AL, Balaban CD. Organization of projections from the raphe nuclei to the vestibular nuclei in rats. *Neuroscience*. 2003;120(2):573-94. doi:10.1016/S0306-4522(02)00952-1
22. Marano E, Marcelli V, Di Stasio E, Bonuso S, Vacca G, Manganelli F et al. Trigeminal stimulation elicits a peripheral vestibular imbalance in migraine patients. *Headache*. 2005;45(4):325-31. doi:10.1111/j.1526-4610.2005.05069.x
23. Shin JH, Kim YK, Kim HJ, Kim JS. Altered brain metabolism in vestibular migraine: comparison of interictal and ictal findings. *Cephalalgia*. 2014;34(1):58-67. doi:10.1177/0333102413498940
24. Russo A, Marcelli V, Esposito F, Corvino V, Marcuccio L, Giannone A et al. Abnormal thalamic function in patients with vestibular migraine. *Neurology*. 2014;82(23):2120-6. doi:10.1212/WNL.0000000000000496
25. Stolte B, Holle D, Naegel S, Diener HC, Obermann M. Vestibular migraine. *Cephalalgia*. 2014;35(3):262-70. doi:10.1177/0333102414535113
26. Bahmad F Jr, DePalma SR, Merchant SN, Bezerra RL, Oliveira CA, Seidman CE et al. Locus for familial migrainous vertigo disease maps to chromosome 5q35. *Ann Otol Rhinol Laryngol*. 2009;118(9):670-6. doi:10.1177/000348940911800912
27. Lee H, Jen JC, Wang H, Chen Z, Mamsa H, Sabatti C et al. A genome-wide linkage scan of familial benign recurrent vertigo: linkage to 22q12 with evidence of heterogeneity. *Hum Mol Genet*. 2006;15(2):251-8. doi:10.1093/hmg/ddi441
28. International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). *Cephalalgia*. 2013;33(9):629-808. doi:10.1177/0333102413485658
29. Furman JM, Marcus DA, Balaban CD. Vestibular igraine: clinical aspects and pathophysiology. *Lancet Neurol*. 2013;12(7):706-15. doi:10.1016/S1474-4422(13)70107-8
30. Cohen JM, Bigal ME, Newman LC. Migraine and vestibular symptoms: identifying clinical features that predict "vestibular migraine". *Headache*. 2011;51(9):1393-7. doi:10.1111/j.1526-4610.2011.01934.x
31. Strupp M, Versino M, Brandt T. Vestibular migraine. *Handb Clin Neurol*. 2010;97:755-71. doi:10.1016/S0072-9752(10)97062-0
32. Cutrer FM, Baloh RW. Migraine-associated dizziness. *Headache*. 1992;32(6):300-4. doi:10.1111/j.1526-4610.1992.hed3206300.x
33. Johnson GD. Medical management of migraine-related dizziness and vertigo. *Laryngoscope*. 1998;108(suppl S85):1-28. doi:10.1111/j.1526-4610.1992.hed3206300.x
34. Reploeg MD, Goebel JA. Migraine-associated dizziness: patient characteristics and management options. *Otol Neurotol*. 2002;23(3):364-71. doi:10.1097/00129492-200205000-00024
35. Lempert T, Neuhauser H. Epidemiology of vertigo, migraine and vestibular migraine. *J Neurol*. 2009;256(3):333-8. doi:10.1007/s00415-009-0149-2
36. Radtke A, Brevern M, Neuhauser H, Hottenrott T, Lempert T. Vestibular migraine: long-term follow-up of clinical symptoms and vestibulo-cochlear findings. *Neurology*. 2012;79(15):1607-14. doi:10.1212/WNL.0b013e31826e264f
37. Lempert, T. Vestibular migraine. *Semin Neurol*. 2013;33(3):212-8. doi:10.1055/s-0033-1354596
38. Vitkovic J, Paine M, Rance G. Neuro-otological findings in patients with migraine- and nonmigraine-related dizziness. *Audiol Neurotol*. 2008;13(2):113-22. doi:10.1159/000111783
39. Brevern M, Zeise D, Neuhauser H, Clarke AH, Lempert T. Acute migrainous vertigo: clinical and oculographic findings. *Brain*. 2005;128(2):365-74. doi:10.1093/brain/awh351
40. Ménière P. Pathologie auriculaire: memoires sur une lésion de l'oreille interne donnant lieu à des symptômes de congestion cérébrale apoplectiforme. *Gaz Med Paris*. 1861;16:597-601.
41. Parker W. Ménière's disease. Etiologic considerations. *Arch Otolaryngol Head Neck Surg*. 1995;121(4):377-82. doi:10.1001/archotol.1995.01890040005001
42. Radtke A, Lempert T, Gresty MA, Brookes GB, Bronstein AM, Neuhauser H. et al. Migraine and Ménière's disease: is there a link? *Neurology*. 2002;59(11):1700-4. doi:10.1212/01.WNL.0000036903.22461.39
43. Griev, SM, Obholzer R, Malitz N, Gibson WP, Parker GD. Imaging of endolymphatic hydrops in Meniere's disease at 1.5 T using phase-sensitive inversion recovery: (1) demonstration of feasibility and (2) overcoming the limitations of variable gadolinium absorption. *Eur J Radiol*. 81(2):331-8. doi:10.1016/j.ejrad.2011.01.073
44. Gürkov R, Kantner C, Strupp M, Flatz W, Krause E, Ertl Wagner B. Endolymphatic hydrops in patients with vestibular migraine and auditory symptoms. *Eur Arch Otorhinolaryngol*. 2014;271(10):2661-7. doi:10.1007/s00405-013-2751-2
45. Nakada T, Yoshida T, Suga K, Kato M, Otake H, Kato K et al. Endolymphatic space size in patients with vestibular migraine and Ménière's disease. *J Neurol*. 2014;261(11):2079-84. doi:10.1007/s00415-014-7458-9
46. Lee SH, Kim JS. Benign paroxysmal positional vertigo. *J Clin Neurol*. 2010;6(2):51-63. doi:10.3988/jcn.2010.6.2.51
47. Brevern M, Radtke A, Clarke AH and Lempert T. Migrainous vertigo presenting as episodic positional vertigo. *Neurology*. 2004;62(3):469-72. doi:10.1212/01.WNL.0000106949.55346.CD
48. Baloh RW. Vertebrobasilar insufficiency and stroke. *Otolaryngol Head Neck Surg*. 1995;112(1):114-7. doi:10.1016/S0194-5998(95)70309-8
49. Maione A. Migraine-related vertigo: diagnostic criteria and prophylactic treatment. *Laryngoscope*. 2006;116(10):1782-86. doi:10.1097/01.mlg.0000231302.77922.c5
50. Neuhauser H, Radtke A, Brevern M, Lempert T. Zolmitriptan for treatment of migrainous vertigo: a pilot randomized

- placebo-controlled trial. *Neurology*. 2003;60(5):882-3. doi:10.1212/01.WNL.0000049476.40047.A3
51. Lepcha A, Amalanathan S, Augustine AM, Tyagi AK, Balraj A. Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. *Eur Arch Otorhinolaryngol*. 2014;271(11):2931-6. doi:10.1007/s00405-013-2786-4
 52. Taghdiri F, Togha M, Razeghi Jahromi S, Refaeian F. Cinnarizine for the prophylaxis of migraine associated vertigo: a retrospective study. *SpringerPlus*. 2014;3(1):231. doi:10.1186/2193-1801-3-231
 53. Bisdorff AR. Treatment of migraine related vertigo with lamotrigine an observational study. *Bull Soc Sci Med Grand Duche Luxemb*. 2004;(2):103-8.
 54. Baier B, Winkenwerder E, Dieterich M. "Vestibular migraine": effects of prophylactic therapy with various drugs: a retrospective study. *J Neurol*. 2009;256(3):436-42. doi:10.1007/s00415-009-0111-3
 55. Obermann M, Strupp M. Current treatment options in vestibular migraine. *Front Neurol*. 2014;5:257. doi:10.3389/fneur.2014.00257
 56. Mikulec AA, Faraji F, Kinsella LJ. Evaluation of the efficacy of caffeine cessation, nortriptyline, and topiramate therapy in vestibular migraine and complex dizziness of unknown etiology. *Am J Otolaryngol*. 2012;33(1):121-7. doi:10.1016/j.amjoto.2011.04.010
 57. Vitkovic J, Winoto A, Rance G, Dowell R, Paine M. Vestibular rehabilitation outcomes in patients with and without vestibular migraine. *J Neurol*. 2013;260(12):3039-48. doi:10.1007/s00415-013-7116-7
 58. Whitney SL, Wrisley DM, Brown KE, Furman JM. Physical therapy for migraine related vestibulopathy and vestibular dysfunction with history of migraine. *Laryngoscope*. 2000;110(9):1528-34. doi:10.1097/00005537-200009000-00022
 59. Wrisley DM, Whitney SL, Furman JM. Vestibular rehabilitation outcomes in patients with a history of migraine. *Otol Neurotol*. 2002;23(4):483-7. doi:10.1097/00129492-200207000-00016